Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection

Chan, P; Li, HB; Zhu, L; Bifano, M; Eley, T; Osawa, M; Ueno, T; Hughes, E; Bertz, R; Garimella, T; AbuTarif, M

Chan, P (reprint author), Bristol Myers Squibb Res & Dev, Lawrenceville, NJ 08648 USA.

CLINICAL PHARMACOKINETICS, 2017; 56 (10): 1173

Abstract

Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. T......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索